Holen Sie sich die Stockscreener-App
36.34
0.03%
0.01
Schlusskurs vom Vortag:
$36.33
Offen:
$36.38
24-Stunden-Volumen:
960.89K
Relative Volume:
0.21
Marktkapitalisierung:
$1.45B
Einnahmen:
$734.86M
Nettoeinkommen (Verlust:
$5.14M
KGV:
290.72
EPS:
0.125
Netto-Cashflow:
$132.71M
1W Leistung:
+0.08%
1M Leistung:
+45.89%
6M Leistung:
+52.31%
1J Leistung:
+59.60%
1-Tages-Spanne:
$36.32
$36.39
1-Wochen-Bereich:
$36.30
$36.66
52-Wochen-Spanne:
$18.80
$36.66
Pacira Biosciences Inc Stock (PCRX) Company Profile
Firmenname
Pacira Biosciences Inc
Sektor
Telefon
650-242-8052
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
36.34 | 1.45B | 734.86M | 5.14M | 132.71M | 0.125 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-23 | Eingeleitet | Oppenheimer | Outperform |
| 2026-09-09 | Eingeleitet | Leerink Partners | Market Perform |
| 2026-08-17 | Fortgesetzt | Truist | Buy |
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-25 | Hochstufung | Truist | Hold → Buy |
| 2025-01-30 | Hochstufung | Truist | Sell → Hold |
| 2024-08-13 | Herabstufung | Truist | Buy → Sell |
| 2024-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Fortgesetzt | JP Morgan | Overweight |
| 2023-12-20 | Eingeleitet | Raymond James | Outperform |
| 2023-08-03 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Fortgesetzt | Wedbush | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-01-03 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-26 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Fortgesetzt | JP Morgan | Neutral |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-04-07 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-20 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-23 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Eingeleitet | BTIG Research | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-06 | Hochstufung | Mizuho | Underperform → Neutral |
| 2019-05-02 | Hochstufung | Stifel | Sell → Hold |
| 2019-02-01 | Herabstufung | Mizuho | Neutral → Underperform |
| 2018-08-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-21 | Bestätigt | Mizuho | Neutral |
| 2018-02-16 | Herabstufung | Needham | Buy → Hold |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-01-04 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Mkt Perform |
Alle ansehen
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
Seven investors report stakes below 5% in Pacira BioSciences (PCRX). - Stock Titan
Form 4 Pacira Pharmaceuticals Inc For: 12 October By Investing.com - Investing.com South Africa
Pacira BioSciences SVP Riker sells $217,920 stock - Investing.com
Pacira BioSciences SVP Riker sells $217,920 stock By Investing.com - Investing.com Canada
Pacira BioSciences SVP Lauren Riker sells $217,920 in stock - Investing.com
Form 4 Pacira Pharmaceuticals Inc For: 10 October By Investing.com - Investing.com South Africa
Pacira BioSciences SVP Lauren Riker sells $217,920 in stock - Investing.com
Form 4 Pacira Pharmaceuticals Inc For: 9 October By Investing.com - Investing.com South Africa
Pacira BioSciences senior vice president Lauren Riker sells $217,920 in stock By Investing.com - Investing.com South Africa
Form 4 Pacira Pharmaceuticals Inc For: 9 October By Investing.com - Investing.com Nigeria
Pacira BioSciences senior vice president Lauren Riker sells $217,920 in stock - Investing.com
After exercising options, Lauren Riker sells 6,000 Pacira BioSciences (PCRX) shares. - Stock Titan
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - Zacks Investment Research
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - TradingView
An offer for all Pacira BioSciences (PCRX) shares is planned but has not yet begun. - Stock Titan
No financing condition applies to the planned Viatris takeover of Pacira BioSciences (PCRX). - Stock Titan
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Pacira BioSciences (Nasdaq: PCRX) Makes 52 Week High on Acquisition News - Investorideas.com
Viatris Inc. entered into a definitive agreement to acquire Pacira BioSciences, Inc. for $1.6 billion. - marketscreener.com
Viatris to Acquire Pacira BioSciences for $36.50 Per Share in $1.65 Billion Cash Deal - Minichart
Why Pacira BioSciences Skyrocketed Today - The Motley Fool
Viatris Acquires Pacira BioSciences for $1.65 Billion - Pharmaceutical Executive
A 6,000-share sale is proposed by Lauren B. Riker of Pacira BioSciences (PCRX). - Stock Titan
With unanimous board backing, Pacira (PCRX) agrees to an all-cash Viatris takeover. - Stock Titan
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies - Viatris Newsroom
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies - PR Newswire
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research
Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom - Orthopedics This Week
A postsurgery pain medicine is planned to launch in four countries; first sales are expected in 2027. - Stock Titan
Discipline and Rules-Based Execution in PCRX Response - Stock Traders Daily
Pacira Biosciences (NASDAQ:PCRX): An Undervalued Value Stock Backed by Cash Flow and Balance Sheet Strength - ChartMill
PACIRA BIOSCIENCES, INC. : LEERINK PARTNERS INITIATES COVERAGE WITH MARKET PERFORM RATING; PRICE TARGET $28 - webull.com
PCRX Initiated Coverage by Leerink Partners -- Rating Market Per - GuruFocus
Five new employees receive Pacira stock awards, vesting over four years - Stock Titan
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
(PCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Pacira BioSciences stock update with limited verified data - ad-hoc-news.de
Truist Financial Initiates Pacira BioSciences(PCRX.US) With Buy Rating - Moomoo
Pacira BioSciences Inc (PCRX) Stock Up 3.5% and Still Undervalued -- GF Score: 81/100 - GuruFocus
Foster & Motley Inc. Buys New Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira (PCRX) Q2 2026 Results: Reported EPS Tops Expectations in Latest Trading; Post-Earnings: The Stock Gains 1.67% for the Current SessionBalance Sheet Strength - vinanet.vn
Rice Hall James & Associates LLC Purchases Shares of 93,396 Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences Inc (PCRX) Chief Medical Officer Jonathan Slo - GuruFocus
Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares of Stock - MarketBeat
Pacira BioSciences (PCRX) CMO sells 3,040 shares in 10b5-1 plan - Stock Titan
Pacira (PCRX) Daily Price Brief: Records a 2.17% Increase to $23.75 in Latest Trading; Technical Focus: $22.56 and $24.94 Define the Nearby Reference Levels on the DayBPI Bull Correction - vinanet.vn
Pacira BioSciences (NASDAQ: PCRX) faces $70.6K share sale in 2026 - Stock Titan
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated at Truist Financial - MarketBeat
Truist Financial Upgrades Pacira BioSciences(PCRX.US) to Buy Rating, Raises Target Price to $30 - Moomoo
Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pacira Biosciences Inc-Aktie (PCRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RIKER LAUREN | Senior Vice President, Finance |
Oct 08 '26 |
Sale |
36.32 |
6,000 |
217,920 |
62,284 |
| RIKER LAUREN | Officer |
Oct 08 '26 |
Proposed Sale |
36.32 |
6,000 |
217,920 |
0 |
| SLONIN JONATHAN | Chief Medical Officer |
Aug 17 '26 |
Sale |
23.23 |
3,040 |
70,619 |
216,384 |
| SLONIN JONATHAN | Officer |
Aug 17 '26 |
Proposed Sale |
23.23 |
3,040 |
70,619 |
0 |
| Ceesay Abraham | Director |
Jun 12 '26 |
Proposed Sale |
23.27 |
9,039 |
210,374 |
0 |
| RIKER LAUREN | Senior Vice President, Finance |
Jun 11 '26 |
Sale |
23.50 |
6,115 |
143,702 |
62,284 |
| RIKER LAUREN | Officer |
Jun 11 '26 |
Proposed Sale |
23.50 |
6,115 |
143,702 |
0 |
| WILLIAMS KRISTEN | Chief Administrative Officer |
Jun 04 '26 |
Sale |
22.27 |
10,259 |
228,468 |
167,062 |
| WILLIAMS KRISTEN | Officer |
Jun 04 '26 |
Proposed Sale |
22.27 |
10,259 |
228,468 |
0 |
| Cross Shawn | Chief Financial Officer |
Apr 23 '26 |
Option Exercise |
16.45 |
12,941 |
212,879 |
118,282 |
1.99%
2.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):